You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
|
|---|---|
| Published in |
Cancer Immunology Research, June 2023
|
| DOI | 10.1158/2326-6066.cir-22-0961 |
| Pubmed ID | |
| Authors |
Poonam N. Desai, Bofei Wang, Andre Fonseca, Pamella Borges, Fatima Zahra Jelloul, Patrick K. Reville, Eric Lee, Christopher Ly, Akshay Basi, Jessica Root, Natalia Baran, Sean M. Post, Qing Deng, Hanxiao Sun, Arif O. Harmanci, Jared K. Burks, Javier A. Gomez, Courtney D. DiNardo, Naval G. Daver, Gheath Alatrash, Marina Konopleva, Michael R. Green, Dinler A. Antunes, Andrew Futreal, Dapeng Hao, Hussein A. Abbas |
| Abstract |
Comprehensive investigation of CD8+ T cells in acute myeloid leukemia (AML) is essential for developing immunotherapeutic strategies beyond immune checkpoint blockade. Herein, we performed single-cell RNA profiling of CD8+ T cells from 3 healthy bone marrow donors and 23 newly diagnosed (NewlyDx) and 8 relapsed/refractory (RelRef) AML patients. Cells co-expressing canonical exhaustion markers formed a cluster constituting <1% of all CD8+ T cells. We identified two effector CD8+ T cell subsets characterized by distinct cytokine and metabolic profiles that were differentially enriched in NewlyDx and RelRef patients. We refined a 25-gene CD8-derived signature correlating with therapy resistance, including genes associated with activation, chemoresistance, and terminal differentiation. Pseudotemporal trajectory analysis supported enrichment of a terminally differentiated state in CD8+ T cells with high CD8-derived signature expression at relapse or refractory disease. Higher expression of the 25-gene CD8 AML signature correlated with poorer outcomes in previously untreated AML patients, suggesting that the bona fide state of CD8+ T cells and their degree of differentiation are clinically relevant. Immune clonotype tracking revealed more phenotypic transitions in CD8 clonotypes in NewlyDx than in RelRef patients. Furthermore, CD8+ T cells from RelRef patients had a higher degree of clonal hyperexpansion associated with terminal differentiation and higher CD8-derived signature expression. Clonotype-derived antigen prediction revealed that most previously unreported clonotypes were patient-specific, suggesting significant heterogeneity in AML immunogenicity. Thus, immunologic reconstitution in AML is likely to be most successful at earlier disease stages when CD8+ T cells are less differentiated and have greater capacity for clonotype transitions. |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 11 | 55% |
| United Kingdom | 1 | 5% |
| France | 1 | 5% |
| India | 1 | 5% |
| Unknown | 6 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 65% |
| Scientists | 5 | 25% |
| Practitioners (doctors, other healthcare professionals) | 2 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 29% |
| Student > Bachelor | 1 | 7% |
| Unknown | 9 | 64% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 14% |
| Biochemistry, Genetics and Molecular Biology | 2 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Unknown | 9 | 64% |
Attention Score in Context
This research output has an Altmetric Attention Score of 41. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2023.
All research outputs
#1,012,386
of 25,410,626 outputs
Outputs from Cancer Immunology Research
#100
of 1,570 outputs
Outputs of similar age
#20,279
of 385,325 outputs
Outputs of similar age from Cancer Immunology Research
#8
of 31 outputs
Altmetric has tracked 25,410,626 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,570 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.9. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 385,325 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.